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Abstract  
Aims: Plasma concentrations of high sensitivity C-reactive protein (hsCRP) are often raised 
in chronic heart failure (CHF) and might indicate inflammatory processes that could be a 
therapeutic target. We aimed to study the associations between hsCRP, mode and cause of 
death in patients with CHF. 
 
Methods and Results: We enrolled 4,423 patients referred to a heart failure clinic serving a 
local population. CHF was defined as relevant symptoms or signs with either a reduced left 
ventricular ejection fraction (LVEF) <40% or raised plasma concentrations of amino-
terminal pro-B type natriuretic peptide (NT-proBNP >125 pg/ml). 
 
The median (IQR) plasma hsCRP for patients diagnosed with CHF (n = 3,756) was 3.9 (1.6-
8.5) mg/L and 2.7 (1.3-5.1) mg/L for those who were not (n=667; p<0.001). Patients with 
hsCRP >10 mg/L (N=809; 22%) were older and more congested than those with hsCRP <2 
mg/L (N=1,117, 30%). 
 
During a median follow up of 53 (IQR: 28-93) months, 1,784 (48%) patients with CHF died.  
Higher plasma hsCRP was associated with greater mortality, independent of age, symptom 
severity, creatinine and NT-proBNP. Comparing a hsCRP >10mg/L to <2mg/L, the hazard 
ratio for all-cause mortality was 2.49 (95% confidence interval: 2.19-2.84); P<0.001), for 
cardiovascular (CV) mortality was 2.26 (1.91-2.68; p<0.001) and for non-CV mortality was 
2.96 (2.40-3.65; p<0.001).  
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Conclusions: In patients with CHF, a raised plasma hsCRP is associated with more 
congestion and a worse prognosis. The proportion of deaths that are non-CV also increases 
with higher hsCRP.    
 
 
Key words: heart failure, CRP, inflammation, mortality, prognosis. 
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Introduction 
Markers of inflammation, such as plasma high sensitivity C-reactive protein (hsCRP), are 
often elevated in patients with heart failure. Inflammation might be the primary cause of 
some cases of heart failure and/or contribute to its progression in many others (1-3); 
importantly, it might also be a therapeutic target (4, 5).  
 
In the Justification for Use of statins in Prevention: an Intervention Trial Evaluating 
Rosuvastatin (JUPITER), amongst apparently healthy men and women with a low density 
lipoprotein cholesterol <3.4mmol/L and an hsCRP ≥2.0 mg/L, rosuvastatin 20 mg/day nearly 
halved the rate of first heart attack, stroke or cardiovascular death compared to placebo (6). 
In a post-hoc analysis of The Controlled Rosuvastatin Multinational Trial in Heart Failure 
(CORONA), patients with ischaemic heart disease and reduced left ventricular ejection 
fraction (HFrEF) assigned to rosuvastatin 10mg/day rather than placebo had fewer 
cardiovascular events and a lower mortality if hsCRP was ≥2mg/L but not below this 
concentration (7). In The Canakinumab Antiinflammatory Thrombosis Outcome Study 
(CANTOS), canakinumab, a human monoclonal antibody targeting interleukin-1 β, reduced 
the incidence of cardiovascular events and lung cancer when compared to placebo in patients 
with a history of myocardial infarction whose hsCRP was ≥2 mg/L (8, 9). In each of these 
three trials treatment reduced plasma concentrations of hsCRP compared to placebo. 
Medicines known to improve outcomes in patients with HFrEF, such as beta-blockers and 
inhibitors of the renin-angiotensin system, may also reduce plasma CRP concentrations (10).  
 
These data suggest that hsCRP may identify patients who might respond differently to 
treatment, possibly because they have an inflammatory component to disease progression. 
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High plasma concentrations of hsCRP are also associated with adverse outcomes in chronic 
heart failure and could be used as an inclusion criterion to identify patients at greater risk as 
well as a potential therapeutic target. However, little is known about the associations between 
hsCRP and mode of death, which could influence either strategy. We now explore these 
issues in a large out-patient cohort. 
 
Methods 
 
Study Population  
 
Between 2002 and 2015, patients with suspected or confirmed heart failure referred from 
both primary and secondary care physicians were enrolled at a single heart failure clinic 
serving a local population of about 500,000 people (The Hull LifeLab). Patients were 
consented for the use of their medical information prior to investigation. Some patients had 
no prior diagnosis of heart failure and were treatment naive, therefore requiring initiation of 
guideline-recommended therapy; others had a pre-existing diagnosis of heart failure and had 
already been initiated on treatment that might, however, require optimisation.  
Information on demography, symptoms & signs, haematology and biochemistry profiles 
(including amino-terminal pro-B-type natriuretic peptide (NT-proBNP)), electrocardiograms 
(ECGs) and echocardiograms were systematically recorded in a dedicated electronic health 
record stored on a secure NHS server. HsCRP was routinely measured during the same visit.  
This specific research question was developed post-hoc. However, data were collected 
prospectively for the purpose of analyses such as this. Heart failure was defined as signs or 
symptoms, confirmed by echocardiographic evidence of significant left ventricular systolic 
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dysfunction (LVSD) or abnormal NT-proBNP levels (>125 ng/L), according to current 
European Society of Cardiology (ESC)-HF guidelines (11). For the 2,023 patients in whom it 
could be measured, left ventricular ejection fraction (LVEF) was <40% in 899 (HFrEF), 
between 40 and 49% in 380 (HFmrEF), and >50% in 744 (HFpEF). In a further 1,733 
patients in whom LVEF could not be calculated, LVEF by visual estimation was considered 
<40% in 509 (HFrEF), 40-49% in 406 (HFmrEF) and ≥50% in 818 (HFpEF). 
The study conformed to the principles outlined in the Declaration of Helsinki and was 
approved by relevant ethical bodies. All participants gave their written informed consent for 
their data to be used for research. 
 
Outcome 
The primary outcome of interest was all-cause mortality. Our hospital is the only one in the 
region offering acute medical services. With patients’ consent, we have access to blood 
results, diagnostic investigations and correspondence on the primary and secondary care 
electronic records. Cause and mode of death are adjudicated at regular intervals in accordance 
with an in-house guideline based on information available from the clinical and electronic 
records (supplementary material - Adjudication process).   
 
 
Statistical methods 
Categorical data are presented as number and percentages; normally distributed continuous 
data as mean ± SD and non-normally distributed continuous variables as median and 
interquartile range. 
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One-way ANOVA and Kruskal-Wallis tests were used to compare continuous variables 
between groups depending on the normality of the distribution, and the chi-squared test was 
used for categorical variables.  
 
Associations between variables and prognosis were assessed using Cox proportional hazards 
models; variables that were significantly (P<0.1) associated with mortality in univariable 
analysis were entered into the multivariable analysis if available in >95% of cases. Missing 
data were not imputed. Assumptions of the models were tested, including multicolinearity 
and proportional hazards.  
 
We prospectively selected variables routinely available in clinic and known to be associated 
with outcome (age, sex, body mass index, systolic blood pressure, history of type II diabetes, 
ischaemic heart disease, NYHA IV/III (vs I/II), atrial fibrillation (vs sinus rhythm) and 
creatinine) to create two baseline models (with and without NT-proBNP). We measured the 
incremental value of the hsCRP (the model’s cumulative discrimination) in predicting 
mortality at 2 years using Harrell's C statistic. The higher discriminative value associated 
with the net reclassification improvement (NRI) and the integrated discrimination 
improvement (IDI) for hsCRP were assessed at 2 years of follow-up. Kaplan-Meier curves 
with the log-rank statistic were used to illustrate outcome. 
 
All analyses were performed using SPSS and Stata software. A 2-sided P value <0.05 was 
considered statistically significant. 
 
Results 
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Patient characteristics (table 1) 
Of 4,423 patients evaluated, 3,756 fulfilled the criteria for HF (Figure 1 supplementary). For 
patients with HFrEF, HFmrEF, or HFpEF, the median (IQR) hsCRP was 4.2 (1.7-9.1) mg/L, 
3.9 (1.6-9.0) mg/L and 3.7 (1.5-7.9) mg/L, respectively (P=0.019), and, in those who did not 
fulfil criteria for HF, 2.7 (1.3-5.1) mg/L (P<0.001 vs the HF phenotypes) (table 1 
supplementary). 
 
Patients with HF and hsCRP >10 mg/L were older, had more symptoms and clinical signs of 
congestion, a higher plasma NT-proBNP and were more likely to receive loop diuretics and 
less likely to receive ACE inhibitors, beta-blockers and statins than those with hsCRP <2 
mg/L (table 1). 
 
Outcome   
During a median follow up of 53 (IQR: 28-93) months, 1,784 (48%) patients with HF died.   
In a multivariable Cox model, increasing hsCRP was independently associated with mortality 
(table 2).  Compared to those with hsCRP <2mg/L, those with hsCRP >10mg/L had more 
than a two-fold increase in mortality (HR: 2.49 (95% CI: 2.19-2.84), P<0.001; HR: 2.42 
(2.12-2.75), p<0.001 when corrected for age and sex, Figure 1). Those who had higher 
plasma concentrations of both NT-proBNP and hsCRP had the worst outcome (Figure 2). 
 
 
Discrimination and reclassification improvement analysis 
 
For the entire cohort of patients with HF, the baseline model without NT-proBNP yielded a c-
index for all-cause mortality of 0.70, which rose to 0.72 when NT-proBNP was added 
(p<0.001). Including hsCRP led to an increase in c-statistic when added to the baseline model 
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with, or without, NT-proBNP for the overall population with HF (table 3) and for each 
phenotype, although this did not reach statistical significance for HFmrEF, perhaps due to 
smaller numbers. In a model including NT-proBNP, hsCRP increased the IDI and NRI for 
all-cause mortality at 2 years in the entire cohort and in each HF phenotype separately (Table 
4).   
 
Associations between hsCRP and mode of death in patients with HF. 
Higher plasma concentrations of hsCRP were associated with greater all-cause mortality at 
two years (table 5). However, the increase in the rate of non-CV deaths (hazard ratio (95% 
confidence interval) for hsCRP >10mg/L to <2mg/L: 2.96 (2.40-3.65; p<0.001)) exceeded 
that for CV deaths (hazard ratio (95% confidence interval): 2.26 (1.91-2.68; p<0.001)) with 
higher plasma hsCRP. Of the 125 deaths in patients with hsCRP<2 mg/L, 71% were 
cardiovascular compared to 57% of the 256 deaths amongst those with hsCRP>10 mg/L. 
Patients with hsCRP >10 mg/L were at higher risk of death from infections (6.1%; 
predominantly respiratory or urinary) and cancer (6.0%: predominantly lung cancer). 
 
When all-cause two-year mortality for each quartile of hsCRP was compared, the mortality 
was similar for each heart failure phenotype, but CV mortality was consistently lower 
amongst patients with HFpEF. This difference was especially striking for patients with an 
hsCRP >10 mg/L amongst whom only 44% of deaths were CV for those with HFpEF 
compared to 66% for HFrEF and 62% for HFmrEF. (Table 5, table 2 supplementary, and 
Figure 3). 
 
Discussion 
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There are three related findings from the present study. Firstly, about 70% of patients with 
heart failure attending a clinic have a hsCRP >2 mg/L, which is associated with a lower 
LVEF and more evidence of clinical congestion; secondly, raised plasma concentrations of 
hsCRP predict a higher all-cause mortality rate, independent of age, symptoms, measures of 
renal function and NT-proBNP; and thirdly, that with increasing hsCRP, the proportion of 
deaths due to non-cardiovascular causes increases, particularly for patients with HFpEF. 
 
Moliner et al (12) found that more than half of patients attending a heart failure clinic had a 
hsCRP >2 ng/L but, in contrast to our findings, they did not find a relation to LVEF. This 
difference may reflect the small number of patients with HFmrEF and HFpEF in their study 
(n=270, 25% of the entire cohort), and differences in the criteria for diagnosing HFpEF. 
 
A few post-hoc studies from large randomised controlled trials have shown that high levels of 
CRP/hsCRP are associated with adverse cardiovascular outcomes in out-patients with HFrEF, 
and there are similar findings from smaller registries enrolling patients with either HFrEF or 
HFpEF (13-15). There are some exceptions. In CORONA, hsCRP was not an independent 
predictor of mortality (16). In the RED-HF trial, in which patients with HFrEF and anaemia 
were enrolled, compared to the lowest tercile, patients in the highest tercile of hsCRP had 
higher mortality, but hsCRP did not improve risk stratification in models that used NT-
proBNP (17). The reasons for the discrepancy include the fact that patients enrolled in 
randomised controlled trials are younger, and far less likely to have complex (and often 
multiple) co-morbidities than those enrolled in “real life” registries such as ours (18). As a 
consequence, patients enrolled in CORONA had a median hsCRP of 3.4 mg/L and in the 
patients in RED-HF who had an event, median hsCRP was 3.5 mg/l (and was only 2.2 mg/L 
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in those without events). In comparison, the patients with HFrEF in our study had a median 
hsCRP of 4.2 mg/L.  
 
We found that including hsCRP modestly increased the discrimination and prediction of 
outcome models, suggesting that inflammation is related to mortality above and beyond other 
commonly used clinical variables, including NT-proBNP.  Thus, there may be some value in 
exploring further inflammation and its treatment in patients with HF.  
 
Inflammation is associated with atherosclerosis (19); and the response to acute infections can 
result in acute myocardial ischaemia (20). Chronic inflammatory conditions, such as 
rheumatoid arthritis, predispose to heart failure through both ischaemic and non-ischaemic 
mechanisms (21, 22), and might cause an increase in plasma concentrations of natriuretic 
peptides (23). Development of venous congestion further activates the innate immune system 
and enhances secretion of pro-inflammatory cytokines, leading to a subsequent rise in 
circulating hsCRP levels (24). An intriguing hypothesis for which there is increasing 
evidence is that heart failure causes inflammation via translocation of bacterial endotoxin 
through oedematous bowel wall. The resulting activation of the innate immune system leads 
to a rise in CRP (25). There is some evidence to suggest that CRP is itself toxic to the 
myocardium (26), suggesting a mechanism by which inflammation may continue to damage 
the heart.  
 
To the best of our knowledge, this is the first paper describing the associations between 
hsCRP with mode of death in ambulatory patients with heart failure. Our findings are 
consistent with a Japanese registry enrolling patients with acute heart failure in whom CRP 
(and not hsCRP) was measured at admission: compared to those in the lowest tercile (<2.9 
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mg/L; N= 1584), patients in the highest tercile of CRP (>11.8 mg/L; n=1596) had a greater 
CV (19.6% v 11.7%) and non-CV (17.9% v 6.0%) mortality at 720 days, with a substantial 
increase in the proportion of deaths due to non-CV causes (from 34 to 48%) (27). 
 
We found that patients with a raised hsCRP had a higher proportion of deaths from non-
cardiovascular causes, particularly cancer. This observation was particularly striking amongst 
patients labelled as having HFpEF. HFpEF is often a diagnosis of exclusion, and it is less 
certain genuinely to represent cardiovascular disease than a diagnosis of HFrEF. In turn, it 
also suggests that a more advanced age and a greater number of comorbidities, rather than the 
extent of cardiac dysfunction, significantly contribute to the poor prognosis of patients with 
HFpEF. Of note, early diagnosis and therapeutic advances, such as better treatments of 
ischaemic heart disease and hypertension, have modified the natural history of HFpEF over 
the past few decades, with a large increase in the proportion of non-cardiovascular deaths in 
this population (28). It is also possible that many of the patients with high hsCRP who 
subsequently died had undetected cancer at the time of heart failure diagnosis, and an 
important consequence is that treatment targeted at heart failure can only have a limited effect 
on outcome in patients with a high hsCRP. However, cancer has long been known to be 
intimately involved with the immune system, and inflammation might contribute to an 
increased risk of developing cancer in patients with heart failure (29, 30). 
 
Using hsCRP might be helpful in designing future clinical trials. A raised hsCRP identifies a 
population at higher risk of adverse outcome. This group might be particularly susceptible to 
treatment directed at inflammation. However, because a higher proportion of the deaths in 
such a group is non-cardiovascular, treatment directed specifically at heart failure might have 
a large effect on cardiovascular death, but a substantially lesser effect on total mortality. In 
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contrast, enrolling only those patients with a low hsCRP might identify a population in whom 
deaths are likely to be cardiovascular, but in whom the absolute death rate is low. These 
observations might be particularly important in patients labelled as having HFmrEF or 
HFpEF, in whom non-cardiovascular deaths might be more common than cardiovascular.  
 
Limitations 
 
We only assessed hsCRP at baseline, as it was not routinely measured in all patients during 
follow-up. Initiation or up-titration of guideline-recommended treatments for HFrEF might 
have reduced plasma concentrations of hsCRP and improved outcome. Other potential 
confounders, for instance time-dependent changes in medications, have not been assessed.  
We did not exclude patients with chronic infections or auto-immune conditions, and we 
cannot exclude the possibility that many patients had an occult malignancy at the time of 
presentation to the cardiology service.  
 
It could be argued that in many patients in whom LVEF was not measured, visual assessment 
of left ventricular systolic dysfunction might have led to misclassification of HF phenotypes. 
The classification system tacitly assumes that echocardiography is an accurate means of 
measuring left ventricular ejection fraction, and that it is a stable measurement from day to 
day. Neither assumption is correct. In our population, it is very probable that many of the 
patients could have been included in a different group had their echocardiogram been 
reported by a different operator or repeated on a different day. 
 
Some readers might not accept an NT-proBNP above 125 pg/ml as being diagnostic of heart 
failure, whether HFmrEF or HFpEF. The definition we used is, however, consistent with 
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recent ESC-HF guidelines (11) and the median NT-proBNP in our patients with HFpEF in 
sinus rhythm was higher than that amongst the patients with HFpEF and sinus rhythm 
enrolled in recently published trials, such as EDIFY, in which the median NT-proBNP was 
375 (IQR: 253-701) ng/l as compared with 389 (IQR: 211-846) ng/l in our population (31). 
 
Conclusions 
In ambulatory patients with HF, higher plasma concentrations of hsCRP are a powerful 
predictor of mortality, and identify those with higher natriuretic peptides who are also more 
likely to die of non-cardiovascular causes.  
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Legend to figures 
 
Figure 1: Kaplan Meier curve for the primary outcome of death from all causes. Compared to 
those with hsCRP <2mg/L, those with hsCRP >10mg/L had more than a two-fold increase in 
mortality (HR: 2.49 (95% CI: 2.19-2.84), unadjusted; and HR: 2.42 (95% CI: 2.12-2.75) 
adjusted for age and sex; P<0.001 for both). 
 
Figure 2: heat map showing the interaction between hsCRP and NT-proBNP and their 
relationship with probability of death at 2 years in patients with heart failure. 
 
Figure 3: Venn diagram showing proportion of deaths at 2 years amongst all patients with 
HF (n=3,538, top row), or by different HF phenotypes,  attributed to cardiovascular disease 
(in blue), cancer (red), infection (green), other (purple), on in whom the more likely cause of 
death was unknown (light blue).  
 
 



Variable Missing 1st Decile of 
HsCRP* 
(n=348) 
HsCRP 
<2 mg/L 
N=1117 
HsCRP 
2-4.9 mg/L 
N=1030 
HsCRP 
5.0-9.9 mg/L 
N=800 
HsCRP 
>10mg/L 
N=809 
10th decile of 
hsCRP* 
(n=376) 
 
P  
Demographics 
Age – years 0 73 (64-79) 74 (66-80) 74 (66-80) 73 (66-80) 75 (68-81) 77 (69-82) 0.008 
Sex (male) – no. (%) 0 228 (66) 722 (65) 647 (63) 470 (59) 494 (61) 248 (66) 0.06 
Body mass index -kg/m2  20 27 (5) 28 (5) 30 (6) 30 (7) 29 (7) 28 (7) <0.001 
Systolic blood pressure – mmHg 14 136  
(118-153) 
139  
(122-156) 
139  
(122-158) 
138  
(120-157) 
132  
(114-153) 
129  
(111-153) 
<0.001 
Heart rate – bpm 29 67 (59-79) 68 (60-80) 71 (60-82) 74 (64-87) 78 (67-91) 80 (69-92) <0.001 
Sinus rhythm – no. (%) 48 267 (77) 839 (76) 715 (70) 540 (69) 537 (67) 257 (69) <0.001 
Peripheral oedema>ankles – no. (%) 335 51 (16) 197 (19) 242 (26) 238 (33) 291 (40) 147 (43) <0.001 
Lung crackles – no. (%) 555 18 (6) 80 (8) 122 (14) 133 (20) 167 (24) 88 (27) <0.001 
Raised JVP – no. (%) 556 23 (8) 84 (9) 122 (14) 124 (18) 165 (24) 82 (26) <0.001 
Diabetes – no. (%) 0 87 (25) 288 (26) 257 (25) 193 (24) 213 (26) 103 (27) 0.74 
h/o Hypertension – no. (%) 0 169 (49) 564 (51) 561 (55) 427 (53) 409 (51) 187 (50) 0.19 
IHD – no. (%) 0 202 (59) 601 (54) 533 (52) 397 (50) 384 (48) 186 (50) 0.039 
Previous or current Smokers – no. (%) 0 36 (10) 150 (13) 162 (16) 142 (18) 157 (19) 74 (20) 0.003 
COPD – no. (%) 0 13 (4) 69 (6) 79 (8) 90 (11) 108 (13) 56 (15) <0.001 
HFrEF – no. (%)  
0 
127 (37) 401 (36) 364 (35) 322 (40) 321 (40) 153 (41)  
0.10 HFmrEF– no. (%) 67 (19) 231 (21) 212 (21) 166 (21) 177 (22) 94 (25) 
HFpEF– no. (%) 154 (44) 485 (43) 454 (44) 312 (39) 311 (38) 129 (34) 
NYHA Class I – no. (%)  
12 
115 (33) 318 (29) 236 (23) 111 (14) 87 (11) 37 (10)  
<0.001 NYHA Class II – no. (%) 169 (49) 551 (50) 496 (48) 392 (49) 346 (43) 155 (41) 
NYHA Class III – no. (%) 63 (18) 240 (21) 284 (28) 274 (34) 339 (42) 158 (42) 
NYHA Class IV – no. (%) 0 (0) 5 (<1) 11 (1) 20 (3) 34 (4) 25 (7) 
Blood results 
NT-proBNP – ng/L 220 727  
(272-1573) 
803  
(322-1781) 
904  
(364-2086) 
1073  
(411-2704) 
1612  
(659-4067) 
2156  
(779-5663) 
<0.001 
NT-proBNP in SR – ng/l 158 495  
(228-1247) 
566  
(261-1328) 
628  
(267-1517) 
737 
(286-2118) 
1197  
(473-3160) 
1418  
(605-4117) 
<0.001 
NT-proBNP in AF – ng/l 57 1428  1496  1682  1861  2613  3919  <0.001 
(989-2544) (1027-2609) (996-2895) (996-3419) (1175-5444) (1980-6670) 
HsCRP – mg/L 0 0.4 (0.3-0.5) 1.0 (0.6-1.4) 3.2 (2.5-4.0) 6.8 (5.8-8.1) 19.0 (13.0-35.0) 37.0 (27.0-59.0) NA 
HsCRP - range 0 0.1-0.6 0.1-1.9 2.0-4.9 5.0-9.9 10.0-299 21-299 NA 
Haemoglobin – g/L 202 13.6 (1.6) 13.5 (1.6) 13.5 (1.7) 13.3 (1.7) 12.5 (1.9) 12.2 (1.8) <0.001 
White cell count - 109.L-1 195 6.6 (5.5-7.8) 6.6 (5.6-8.0) 7.1 (6.0-8.4) 7.5 (6.2-8.7) 8.0 (6.6-9.7) 8.3 (6.7-10.3) <0.001 
Neutrophils- 109.L-1 551 4.0 (3.3-4.8) 4.1 (3.3-5.0) 4.4 (3.6-5.5) 4.8 (3.8-5.8) 5.4 (4.3-6.7) 5.7 (4.6-7.3) <0.001 
Lymphocytes - 109.L-1 551 1.7 (1.4-2.1) 1.7 (1.3-2.2) 1.7 (1.3-2.2) 1.7 (1.2-2.1) 1.5 (1.1-2.0) 1.4 (1.0-1.8) <0.001 
Plasma viscosity - mPaSec 984 1.6 (0.1) 1.6 (0.1) 1.7 (0.1) 1.7 (0.2) 1.8 (0.2) 1.9 (0.2) <0.001 
Creatinine-µmol/L 85 93 (80-113) 94 (80-116) 99 (82-119) 101 (81-129) 107 (86-141) 115 (88-150) <0.001 
Urea - mmol/L 89 6.3 (5.2-8.2) 6.4 (5.1-8.4) 6.6 (5.1-8.9) 6.9 (5.2-9.6) 7.7 (5.6-11.1) 8.0 (5.8-11.9) <0.001 
Albumin – g/L 104 40 (3) 39 (3) 38 (3) 37 (3) 34 (4) 33 (4) <0.001 
Cholesterol  -mmol/L 208 4.4 (1.2) 4.5 (1.2) 4.6 (1.2) 4.7 (1.4) 4.4 (1.2) 4.6 (1.3) <0.001 
Bilirubin – µmol/L 105 15 (12-18) 14 (12-18) 14 (12-18) 14 (11-18) 13 (11-18) 13 (10-18) <0.001 
ALP - iu/L 95 64 (52-76) 66 (54-80) 71 (58-88) 78 (63-96) 86 (69-111) 88 (71-114) <0.001 
ALT - iu/L 97 21 (17-27) 21 (17-27) 21 (17-27) 19 (15-26) 19 (15-26) 18 (14-26) <0.001 
#Medications 
Loop diuretic – no (%) 0 169 (49) 594 (53) 655 (64) 536 (67) 604 (75) 285 (76) <0.001 
Mineralocorticoid antagonists– no (%) 0 82 (24) 241 (22) 194 (19) 164 (21) 177 (22) 80 (21) 0.33 
ACE-I or ARB– no (%) 0  258 (74) 796 (71) 767 (75) 539 (67) 543 (67) 231 (61) 0.001 
Beta-blockers– no (%) 0 222 (64) 710 (64) 635 (62) 432 (54) 434 (54) 198 (53) <0.001 
Statins – no.% 0 231 (66) 720 (64) 576 (56) 388 (49) 355 (44) 166 (44) <0.001 
Echocardiography 
##LVEF (when measured) - % 1733 46 (32-56) 45 (34-56) 42 (33-56) 40 (30-55) 40 (30-55) 39 (30-50) <0.001 
LAD - cm 436 4.1 (0.8) 4.1 (0.8) 4.2 (0.8) 4.3 (0.8) 4.2 (0.8) 4.2 (0.8) 0.003 
 
 
Table 1 – Characteristics of patients with HF (n = 3,756) stratified by plasma concentration of HsCRP.  *Patients in the lowest decile are a 
subset of those in the lowest quartile (counted in both). *Patients in the highest decile are a subset of those in the highest quartile (counted in 
both). # Medications recorded at baseline prior to changes subsequent to initial referral ## LVEF was measured in 2,023 patients (54%) and was 
visually estimated in the remainder as <40%, 40- % o  ≥50%. Abbreviations used: JVP – jugular venous pressure; IHD – ischaemic heart 
disease; HFrEF - heart failure with reduced ejection fraction; HFmrEF - heart failure with midrange ejection fraction; HFpEF - heart failure with 
preserved ejection fraction; SR – sinus rhythm; AF – atrial fibrillation; ALT - alanine aminotransferase; ALP - alkaline phosphatase; LVEF – 
left ventricular ejection fraction; LAD – left atrial diameter.  
 Univariable analysis Multivariable analysis 
Variable HR (95% CI) χ2 p-value HR (95% CI) χ2 p-value 
Age - years 1.05 (1.05-1.06) 364 <0.001 1.05 (1.04-1.05) 185 <0.001 
Sex (male) - no. (%) 1.15 (1.05-1.27) 8 0.005 1.31 (1.16-1.47) 20 <0.001 
Body mass index -kg/m2 0.97 (0.96-0.97) 62 <0.001 0.99 (0.98-1.00) 7 0.009 
Systolic blood pressure – mmHg 0.99 (0.99-1.00) 46 <0.001 0.99 (0.99-1.00) 8 0.005 
Heart rate – bpm 1.01 (1.00-1.01) 32 <0.001    
AF – (Yes vs no) 1.34 (1.21-1.48) 31 <0.001    
Peripheral oedema  (>ankles vs <) 1.78 (1.61-1.98) 116 <0.001    
Lung crackles – (Yes vs no) 1.93 (1.70-2.19) 106 <0.001    
Raised JVP – (Yes vs no) 1.96 (1.73-2.23) 107 <0.001    
Diabetes - (Yes vs no) 1.17 (1.05-1.31) 8 0.005    
Hypertension - (Yes vs no) 0.99 (0.90-1.09) 0 0.89    
IHD - (Yes vs no) 1.13 (1.02-1.24) 6 0.014    
Previous or current Smokers – no. (%) 1.08 (0.96-1.23) 2 0.20    
HFrEF (vs other phenotypes) 1.25 (1.14-1.37) 22 <0.001    
HFrEF (vs HFpEF) 1.31 (1.18-1.45) 26 <0.001    
HFrEF (vs HFmrEF) 1.16 (10.3-1.31) 6 0.018    
HFmrEF (vs HFpEF) 1.13 (0.89-1.28) 3 0.073    
NYHA Class IV/III vs I/II 2.05 (1.86-2.25) 215 <0.001 1.54 (1.37-1.72) 55 <0.001 
LogNTproBNP  2.89 (2.64-3.17) 507 <0.001 1.71 (1.51-1.95) 68 <0.001 
LogHsCRP 1.85 (1.70-2.02) 207 <0.001 1.33 (1.19-1.48) 27 <0.001 
Haemoglobin – g/L 0.82 (0.80-0.84) 199 <0.001    
White cell count - 109.L-1 1.03 (1.02-1.04) 36 <0.001    
Neutrophils- 109.L-1 1.03 (1.02-1.04) 90 <0.001    
Lymphocytes - 109.L-1 0.89 (0.83-0.95) 11 0.001    
Plasma viscosity - mPaSec 3.87 (2.77-5.41) 63 <0.001    
Creatinine-µmol/L 1.003 (1.002-1.003) 188 <0.001    
Urea - mmol/L 1.06 (1.05-1.06) 354 <0.001 1.02 (1.01-1.03) 24 <0.001 
Albumin – g/L 0.89 (0.88-0.90) 342 <0.001 0.97 (0.95-0.99) 14 <0.001 
Cholesterol  -mmol/L 0.92 (0.89-0.96) 15 <0.001    
Bilirubin – µmol/L 1.01 (1.00-1.01) 22 <0.001    
ALP - iu/L 1.01 (1.00-1.01) 223 <0.001 1.003 (1.002-1.004) 27 <0.001 
ALT - iu/L 0.99 (0.98-0.99) 18 <0.001    
LAD - cm 1.27 (1.19-1.35) 57 <0.001    
 
 
Table 2 – Univariable and multivariable Cox proportional hazard models for all-cause mortality in patients with heart failure. Variables entered 
in the multivariable model are highlighted in bold. Abbreviations used: JVP – jugular venous pressure; IHD – ischaemic heart disease; HFrEF - 
heart failure with reduced ejection fraction; HFmrEF - heart failure with midrange ejection fraction; HFpEF - heart failure with preserved 
ejection fraction; AF – atrial fibrillation; ALT - alanine aminotransferase; ALP - alkaline phosphatase; LVEF – left ventricular ejection fraction; 
LAD – left atrial diameter.  
 
 
 
Model comparison C-index 
 
 
-index 
(by adding 
log(hsCRP)) 
 
 
 
Compared to model 1/model M2 
(t-statistic, p-value) 
Model 1 
All HF Patients (n =3,413) 0.70  0.02 t=4.17, p<0.0001 
HFrEF (n =1,157) 0.69  0.02 t=2.80, p=0.005 
HFmrEF (n =764) 0.72  0.01 t=1.35, p=0.18 
HFpEF (n =1,492) 0.70  0.03 t=3.08, p=0.002 
Model 2 
All HF Patients (n =3,413) 0.72  0.02 t=3.86, p<0.0001 
HFrEF (n =1,157) 0.73  0.01 t=1.95, p=0.05 
HFmrEF (n =764) 0.73  0.01 t=1.49, p=0.14 
HFpEF (n =1,492) 0.74  0.02 t=3.08, p=0.002 
 
Table 3: Model discrimination.*Model 1: Age, Sex, BMI, SBP, DM, IHD, NYHA IV/III vs 
I/II, AF and creatinine. **Model 2: model M1 + log(NT-proBNP). Results are shown in bold 
for all patients and in Italic for each HF phenotype. Abbreviations used: HFrEF - heart failure 
with reduced ejection fraction; HFmrEF - heart failure with midrange ejection fraction; 
HFpEF - heart failure with preserved ejection fraction. 
 
 
 
 
All HF patients (n=3,413)# 
Model comparison cNRI (95%CI) p-value IDI (95%CI) p-value 
Model 1 + log(hsCRP) 0.36 (0.27-0.45) <0.0001 0.021 (0.015-0.027) <0.0001 
Model 2 + log(hsCRP) 0.30 (0.21-0.39) <0.0001 0.013 (0.007-0.0189) <0.0001 
HFrEF population (n=1,157) 
Model 1 + log(hsCRP) 0.36 (0.20-0.52) <0.0001 0.019 (0.009-0.029) 0.0003 
Model 2 + log(hsCRP) 0.22 (0.06-0.38) 0.003 0.008 (0.0002-0.016) 0.031 
HFmrEF population (764) 
Model 1 + log(hsCRP) 0.38 (0.20-0.56) <0.0001 0.016 (0.004-0.028) 0.008 
Model 2 + log(hsCRP) 0.30 (0.12-0.48) 0.0013 0.010 (0.0002-0.020) 0.041 
HFpEF Population (n=1,492) 
Model 1 + log(hsCRP) 0.34 (0.20-0.48) <0.0001 0.023 (0.013-0.033) <0.0001 
Model 2 + log(hsCRP) 0.30 (0.16-0.44) <0.0001 0.015 (0.005-0.025) 0.0013 
 
Table 4: Improvement in prediction of all-cause mortality at 2 years by using log(hsCRP). 
Model 1: Age, Sex, BMI, SBP, DM, IHD, NYHA IV/III vs I/II, AF and creatinine. Model 2: 
model 1 + log(NtproBNP). # excludes 218 patients who had follow-up shorter than 2 years or 
those with missing values (n=125). 
 
Cause and mode of death at 2 years in 3,538 patients with HF, according to phenotype and hsCRP levels # 
 HFrEF HFmrEF HFpEF 
  
All 
N=1353 
HsCRP 
<2  
mg/L 
N=381 
HsCRP 
2.0-4.9 
mg/L 
N=354 
HsCRP 
5.0-9.9 
mg/L 
N=310 
HsCRP 
>10 mg/L 
N=308 
 
All 
N=743 
HsCRP 
<2 
 mg/L 
N=221 
HsCRP 
2.0-4.9 
mg/L 
N=203 
HsCRP 
5.0-9.9 
mg/L 
N=156 
HsCRP 
>10 
mg/L 
N=163 
All 
N=1442 
HsCRP 
<2 mg/L 
N=455 
HsCRP 
2.0-4.9 
mg/L 
N=418 
HsCRP 
5.0-9.9 
mg/L 
N=286 
HsCRP 
>10 
mg/L 
N=283 
2-Y mortality 20.7% 
(n=280) 
13.1% 
(n=50) 
13.3% 
(n=47) 
24.2% 
(n=75) 
35.1% 
(n=108) 
18.8% 
(n=140) 
13.1% 
(n=29) 
12.3 % 
(n=25) 
19.8% 
(n=31) 
33.8% 
(n=55) 
17.3% 
(n=250) 
10.1% 
(n=46) 
13.9% 
(n=58) 
18.5% 
(n=53) 
32.9% 
(n=93) 
Cause and mode of Death 
CV 14.4% 
(n=195) 
10.2% 
(n=39) 
9.6% 
(n=34) 
16.5% 
(n=51) 
23.1% 
(n=71) 
11.4% 
(n=85) 
9.5% 
(n=21) 
5.9% 
(n=12) 
11.5% 
(n=18) 
20.9% 
(n=34) 
9.2%  
(n=133) 
6.4%  
(n=29) 
7.4%  
(n=31) 
11.2% 
(n=32) 
14.5% 
(n=41) 
Terminal HF 5.0% 
(n=68) 
2.9% 
(n=11) 
3.9% 
(n=14) 
6.5% 
(n=20) 
7.5% 
(n=23) 
2.4% 
(n=18) 
2.7% 
(n=6) 
0.5%
 (n=1) 
3.2% 
(n=5) 
3.7% 
(n=6) 
2.5% 
(n=36) 
1.8% 
(n=8) 
1.2% 
(n=5) 
3.1% 
(n=9) 
4.9% 
(n=14) 
Sudden 8.2% 
(n=112) 
6.3% 
(n=24) 
5.1% 
(n=18) 
8.4% 
(n=26) 
14.3 % 
(n=44) 
7.1% 
(n=53) 
5.4% 
(n=12) 
4.9% 
(n=10) 
7.7% 
(n=12) 
11.7% 
(n=19) 
5.3% 
(n=76) 
3.7% 
(n=17) 
4.5% 
(n=19) 
6.3% 
(n=18) 
7.8% 
(n=22) 
Other CV 1.2% 
(n=15) 
1.0% 
(n=4) 
0.6% 
(n=2) 
1.6% 
(n=5) 
1.3% 
(n=4) 
1.9% 
(n=14) 
1.4% 
(n=3) 
0.5% 
(n=1) 
0.6% 
(n=1) 
5.5% 
(n=9) 
1.4% 
(n=21) 
0.9% 
(n=4) 
1.7% 
(n=7) 
1.8% 
(n=5) 
1.8% 
(n=5) 
Non-CV 6.3% 
(n=85) 
2.9% 
(n=11) 
3.7% 
(n=13) 
7.7% 
(n=24) 
12.0% 
(n=37) 
7.4% 
(n=55) 
3.6% 
(n=8) 
6.4% 
(n=13) 
8.3% 
(n=13) 
12.9% 
(n=21) 
8.1% 
(n=117) 
3.7% 
(n=17) 
6.5% 
(n=27) 
7.3% 
(n=21) 
18.4% 
(n=52) 
Infection 2.6% 
(n=35) 
1.3% 
(n=5) 
1.7% 
(n=6) 
3.5% 
(n=11) 
4.2% 
(n=13) 
3.0% 
(n=22) 
0.5% 
(n=1) 
2.0% 
(n=4) 
3.2% 
(n=5) 
7.4% 
(n=12) 
3.7% 
(n=53) 
1.7% 
(n=8) 
3.8% 
(n=16) 
2.8% 
(n=8) 
7.4% 
(n=21) 
Cancer 2.5% 
(n=34) 
0.8% 
(n=3) 
1.1% 
(n=4) 
2.6% 
(n=8) 
6.2% 
(n=19) 
3.1% 
(n=23) 
1.8% 
(n=4) 
3.4% 
(n=7) 
3.8% 
(n=6) 
3.7% 
(n=6) 
2.6% 
(n=38) 
0.9% 
(n=4) 
1.5% 
(n=6) 
2.8% 
(n=8) 
7.1% 
(n=20) 
Other Non 
CV/Unknown* 
1.2% 
(n=16) 
0.8% 
(n=3) 
0.9% 
(n=3) 
1.6% 
(n=5) 
1.6% 
(n=5) 
1.3% 
(n=10) 
1.3% 
(n=3) 
1.0% 
(n=2) 
1.3% 
(n=2) 
1.8% 
(n=3) 
1.8% 
(n=26) 
1.1% 
(n=5) 
1.2% 
(n=5) 
1.7% 
(n=5) 
3.9% 
(n=11) 
Origin of Cancer Attributed to Death 
Lung 13 1 3 2 7 5 1 1 1 2 13 0 3 1 9 
Prostate 2 0 0 0 2 2 0 2 0 0 1 0 0 1 0 
GI 5 1 0 2 2 9 3 1 3 2 9 2 3 1 3 
Blood 4 0 0 2 2 1 0 0 1 0 5 1 0 2 2 
Renal/Urinary 2 0 1 0 1 1 0 0 0 1 3 0 0 1 2 
Breast 2 0 0 0 2 1 0 0 1 0 2 0 0 2 0 
 
Table 5. Rate, cause and mode of death at 2 years (2-Y) in all patients with HF, according to different HF phenotypes and cut-offs of HsCRP. 
Abbreviations used: CV: cardiovascular; GI: gastrointestinal; HF: heart failure; HFrEF - heart failure with reduced ejection fraction; HFmrEF - 
heart failure with midrange ejection fraction; HFpEF - heart failure with preserved ejection fraction.# excludes 218 patients who had follow-up 
shorter than 2 years. * The mode and cause of death were adjudicated as “unknown” in two patients only (one with HFmrEF and one with 
HFpEF).  
 
 
Pancreas 3 1 0 1 1 0 0 0 0 0 1 1 0 0 0 
Liver 1 0 0 0 1 0 0 0 0 0 1 0 0 0 1 
Other/Unknown 2 0 0 1 1 4 0 3 0 1 3 0 0 0 3 
